Cadrenal Therapeutics (CVKD) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Strategic positioning and program overview

• Focuses on bridging gaps in anticoagulation for rare and high-risk patients, especially where current DOACs and warfarin are inadequate.

• Lead program Tecarfarin targets end-stage renal disease with atrial fibrillation and patients with implanted devices, holding orphan drug designations.

• VLX-1005, recently acquired, targets heparin-induced thrombocytopenia (HIT) and has completed phase 2; Fruinexian, a short-acting Factor XI inhibitor, is in phase 2 for cardiovascular surgery.

• Addresses market needs where reversibility and safety are concerns, especially after the withdrawal of Andexxa, a key reversal agent.

• Programs are positioned to serve patients who cannot use DOACs and require alternatives to long-standing therapies.

VLX-1005 and 12-LOX inhibition

• VLX-1005 is a first-in-class 12-LOX inhibitor, developed to intervene upstream in immune-mediated platelet activation, offering a novel approach to HIT.

• Chosen for HIT due to a clear mechanistic tie-in and high unmet need, with current treatments carrying significant bleeding risks.

• HIT is a rare but serious complication of heparin therapy, leading to high morbidity and mortality; VLX-1005 aims to reduce bleeding risk by targeting disease pathogenesis.

• Orphan Drug and Fast Track designations accelerate development, reduce costs, and provide regulatory advantages.

• Broader applicability of 12-LOX inhibition is being explored in other immune-mediated and thrombo-inflammatory diseases, including type 1 diabetes.

Long-term strategy and market opportunity

• Portfolio now spans acute immune-mediated platelet activation and acute care coagulation, aiming to replace outdated therapies for underserved populations.

• Tecarfarin offers a kidney-friendly alternative for patients with mechanical heart valves or advanced renal disease who cannot use DOACs.

• VLX-1005 and Tecarfarin both have Orphan and Fast Track designations, supporting rapid advancement.

• Combined peak annual revenue opportunity across targeted indications is estimated at $3 billion.

• VLX-1005 is expected to be the primary value driver in the next 3–5 years, followed by Tecarfarin and Fruinexian.